STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 228.1

Change

-2.85 (-1.23)%

Market Cap

USD 0.75B

Volume

139.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.33 (+0.74%)

USD 61.53B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.90 (+0.17%)

USD 12.47B
WRD:PA HSBC ETFs Public Limited Compa..

+0.03 (+0.10%)

USD 10.38B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.63 (-0.67%)

USD 8.83B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+2.35 (+0.51%)

USD 8.12B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.22 (+0.06%)

USD 7.14B
HHH:PA HSBC ETFs Public Limited Compa..

+0.09 (+0.17%)

USD 7.04B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.04 (+0.20%)

USD 6.51B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.69 (+0.18%)

USD 5.52B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

+0.16 (+0.10%)

USD 5.01B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.62% 62% D 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.62% 62% D 70% C-
Trailing 12 Months  
Capital Gain 19.24% 43% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.24% 43% F 61% D-
Trailing 5 Years  
Capital Gain 52.43% 68% D+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.43% 68% D+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.70% 58% F 60% D-
Dividend Return 8.70% 55% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.41% 76% C+ 88% B+
Risk Adjusted Return 103.46% 95% A 99% N/A
Market Capitalization 0.75B 75% C 76% C+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike